
Piramal Pharma (PPLPHARMA) Share Price Touches Fresh 52-Week High of Rs 239.40, Trades 2.02% Lower
Updated: 29 Oct 2026 • 12:56 pm
Posted by:

Piramal Pharma Share Price stands at Rs 228.10 as of 29 October 2026 at 12:52 PM IST, down 2.02% from the previous close of Rs 232.80, after the stock touched a fresh 52-week high of Rs 239.40 today. The company’s market capitalisation is Rs 26,420.60 crore.
This Piramal Pharma Stock News update covers what happened today, what the latest Univest figures show on valuation and returns, and how the stock compares with its industry and listed peers. According to Univest data, the price event is confirmed, but no company-specific catalyst is established, so the analysis below sticks to price action, fundamentals, benchmarks and peer numbers.
Piramal Pharma Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 228.1 |
| Previous Close | Rs 232.8 |
| Today's Move | Rs -4.7 (-2.02%) |
| Open | Rs 231.4 |
| High | Rs 239.4 |
| Low | Rs 225.75 |
| Market Capitalisation | Rs 26,420.6 crore |
Readers following Piramal Pharma Share Price Today in the Indian stock market can monitor whether the stock returns toward its 52-week high of Rs 239.40, how its P/B ratio of 3.81 compares with the industry median of 2.74, and how future filings compare with the Sep 2026 revenue of Rs 2,617.06 crore.
Piramal Pharma Ltd. (PPLPHARMA) traded at Rs 228.1 versus the previous close of Rs 232.8, a fall of 2.02%. The stock opened at Rs 231.4, reached a high of Rs 239.4 and touched a low of Rs 225.75.
Piramal Pharma Share Price Today is Rs 228.10, a fall of Rs 4.70 or 2.02% from the previous close of Rs 232.80. The stock touched a fresh 52-week high of Rs 239.40 and now trades Rs 11.30 below that level, which keeps the Piramal Pharma 52 Week High event in focus.
The stock opened at Rs 231.40, Rs 1.40 below the previous close, and touched a low of Rs 225.75 during the day, Rs 7.05 under that close. From there, Piramal Pharma moved between Rs 225.75 and Rs 239.40, a range of Rs 13.65, and it now trades Rs 3.30 below its opening level.
Because the 52-week high and the day high are the same price, this one-year high was set earlier today. The Piramal Pharma Share Price Update therefore describes a stock that opened below its previous close, reached a yearly peak and now trades Rs 2.35 above the day low and below the previous close. With the price event confirmed, the next question is whether valuation and returns add context.
For readers comparing Piramal Pharma Share Price against earlier levels, the useful reference points are the previous close of Rs 232.80, the opening price of Rs 231.40 and the 52-week high of Rs 239.40. The gap between the previous close and the current price is Rs 4.70, which is the 2.02% move reported by Univest. These stock updates are based on figures as of 12:52 PM IST and can change as trading continues through the day.
Piramal Pharma Ltd. (PPLPHARMA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 26,420.6 crore |
| P/B Ratio | 3.81x |
| ROE | -4.04% |
| ROCE | 1.24% |
| EPS | Rs -1.57 |
| Book Value Per Share | Rs 61.18 |
| Dividend Yield | 0% |
Piramal Pharma Ltd. (PPLPHARMA) fundamental metrics show P/B 3.81x, ROE -4.04%, ROCE 1.24%. Read together, these ratios describe the company’s position rather than a recommendation.
Piramal Pharma Ltd. has a market capitalisation of Rs 26,420.6 crore, which gives readers a sense of company size before judging valuation. On valuation, P/B at 3.81x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of -4.04% and ROCE of 1.24%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs -1.57, book value per share of Rs 61.18, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.57x, median ROE of 11.23%, median ROCE of 13.1%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Benchmark Median P/E | 31.57x |
| Benchmark Average P/E | 46.23x |
| Benchmark P/E Range | 3.21x to 598.47x |
| Company P/B Ratio | 3.81x |
| Benchmark Median P/B | 2.74x |
| Company ROE | -4.04% |
| Benchmark Median ROE | 11.23% |
| Company ROCE | 1.24% |
| Benchmark Median ROCE | 13.1% |
| Company Market Capitalisation | Rs 26,420.6 crore |
| Benchmark Median Market Cap | Rs 711.9 crore |
Piramal Pharma Ltd. (PPLPHARMA) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Piramal Pharma Ltd. (PPLPHARMA) has a ROE of -4.04%, which is below the benchmark median of 11.23%, a difference of -135.98%. Piramal Pharma Ltd. (PPLPHARMA) has a ROCE of 1.24%, which is below the benchmark median of 13.1%, a difference of -90.53%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| RUBICON RESEARCH LIMITED | RUBICON | 25,078.35 | 89.89 | 19.3 | 27.84 | 29.22 |
| Neuland Laboratories Ltd. | NEULANDLAB | 24,751.49 | 51.59 | 12.71 | 21.43 | 27.5 |
| Wockhardt Ltd. | WOCKPHARMA | 30,629.48 | 76 | 6.17 | 4.29 | 6.79 |
| Granules India Ltd. | GRANULES | 22,745.75 | 34.6 | 4.68 | 14.13 | 15.74 |
| AMI Organics Ltd. | ACUTAAS | 31,066.41 | 69.1 | 16.34 | 24.08 | 32.42 |
Its ROE of -4.04% compares with a peer median of 21.43% across the companies shown in the table. ROCE stood at 1.24% versus the displayed peer median of 27.5%, providing a capital-efficiency comparison. Piramal Pharma Ltd. (PPLPHARMA) has a market capitalisation of Rs 26,420.6 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Piramal Pharma
- Piramal Pharma Share Price is Rs 228.10, down 2.02% from the previous close of Rs 232.80.
- The stock touched a fresh 52-week high of Rs 239.40 today, and the day high equals that level.
- The P/B ratio of 3.81 compares with an industry median of 2.74 across 195 companies.
- ROE of -4.04% and ROCE of 1.24% are below the industry medians of 11.23% and 13.10%.
- Revenue for the Sep 2026 quarter is Rs 2,617.06 crore, and market capitalisation is Rs 26,420.60 crore.
About Piramal Pharma
Piramal Pharma Ltd. is classified under the Healthcare sector and the Pharmaceuticals & Drugs industry in the latest Univest figures. The stock is quoted under the symbol PPLPHARMA, and its latest quarterly revenue label is Sep 2026. Market capitalisation, valuation multiples and peer figures for the company are covered in the sections above.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What is the Piramal Pharma Share Price today?
Ans. Piramal Pharma Share Price is Rs 228.10 as of 29 October 2026 at 12:52 PM IST, down Rs 4.70 or 2.02% from the previous close of Rs 232.80, within a day range of Rs 225.75 to Rs 239.40.
Has Piramal Pharma touched a 52-week high today?
Ans. Yes. According to latest Univest data, Piramal Pharma touched a fresh 52-week high of Rs 239.40 today. The stock now trades at Rs 228.10, which is Rs 11.30 below that one-year high, and the day high matches it.
How has the Piramal Pharma stock moved today?
Ans. The Piramal Pharma stock is down 2.02%, a fall of Rs 4.70, from the previous close of Rs 232.80. It opened at Rs 231.40, touched a low of Rs 225.75 and then reached Rs 239.40.
What is the Piramal Pharma market cap?
Ans. Piramal Pharma Market Cap is Rs 26,420.60 crore according to the latest Univest figures. The Pharmaceuticals & Drugs benchmark of 198 companies has a median market capitalisation of Rs 711.90 crore and an average of Rs 13,753.79 crore.
What is the Piramal Pharma P/B ratio compared with the industry?
Ans. Piramal Pharma has a P/B ratio of 3.81 against an industry median of 2.74 and an average of 4.02. That places the P/B 39.05% above the median across the 195 companies with a reported P/B.
What are the Piramal Pharma ROE and ROCE?
Ans. Piramal Pharma reports ROE of -4.04% and ROCE of 1.24%. The industry medians are 11.23% for ROE and 13.10% for ROCE, so both return ratios sit below the Pharmaceuticals & Drugs benchmark across 197 companies.
What are the Piramal Pharma EPS, book value and dividend yield?
Ans. Piramal Pharma reports EPS of Rs -1.57 and book value of Rs 61.18 per share, with a P/B ratio of 3.81. Dividend yield is 0%, a historical measure of payout relative to the current price, not a promise.
How does Piramal Pharma compare with its listed peers?
Ans. Piramal Pharma has a P/B of 3.81, below all five listed peers shown, which range from 4.68 to 19.30. Its ROE of -4.04% and ROCE of 1.24% are also below each peer, while its market cap is above three of them.
Track Piramal Pharma Share Price on Univest
Use Piramal Pharma Ltd. (PPLPHARMA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Users can track the live Piramal Pharma Share Price, fundamental ratios, 52-week levels and market insights on Univest. The Piramal Pharma Share Price Live page brings price, valuation and peer figures together, so readers can compare today’s 52-week high of Rs 239.40 with the latest numbers as they update through the day.
Recent Articles

HUL Revenue Growth Hits a 14-Quarter High, but a Margin Squeeze May Be Here to Stay: What Investors Should Check
29 October 2026

Highway Infrastructure Share Price Jumps 65% in a Month: What NHAI Toll Orders Explain and What Thin Margins Say
29 October 2026

Jio Platforms vs Bharti Airtel vs Vodafone Idea: How the Three Telecom Stocks Compare After the Jio Listing
29 October 2026

Nifty Outlook After the Fed Pause: Can Bulls Take Charge or Will a Fresh RBI Rate Hike Spoil the Rally?
29 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
HUL Revenue Growth Hits a 14-Quarter High, but a Margin Squeeze May Be Here to Stay: What Investors Should Check
Highway Infrastructure Share Price Jumps 65% in a Month: What NHAI Toll Orders Explain and What Thin Margins Say
Jio Platforms vs Bharti Airtel vs Vodafone Idea: How the Three Telecom Stocks Compare After the Jio Listing
Nifty Outlook After the Fed Pause: Can Bulls Take Charge or Will a Fresh RBI Rate Hike Spoil the Rally?
Zensar Technologies Share Price Jumps 8% After Q2 FY27 Results: What BFSI Growth and AI Deals Mean for the Rally

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





